mspipeline

I added two studies to the phase 1 list: Low Fat Diet and Linoleic Acid.

Based on this press release, I added Valomaciclovir (EPB-348) to the phase 1 list.

I removed T-Cell Vaccination (Transnational University Limburg, Belgium /Netherlands) from the phase 2 list because I couldn’t find any indication that there is a trial either planned or on-going.

I removed Pirfenidone (aka Deskar) from the phase 2 list because I can find no evidence that there are any further MS trials planned or on-going, despite somewhat promising results in a phase 2 SPMS trial a few years ago.

I removed Pioglitazone (Actos) from the phase 2 list because it has been 2 years since the initial study was reported and I haven’t found any information about a new trial planned or in progress. Takeda, the company that produces Actos, does not mention anything about an MS trial in their pipeline.

I removed N-acetyl-L-cysteine (with copaxone) from the phase 2 list because the trial is complete and I can find no evidence of other on-going trials.

I removed Inosine (Thomas Jefferson University) from the phase 2 list because the trial is complete and I can’t find any evidence of additional inosine trials in progress.

I removed MLN1202 (Millenium) from the phase 2 list because I found no evidence that it was anything more than a figment of my imagination.

http://www.millennium.com/science/pipeline.asp

I moved lipoic acid from phase 2 to phase 1 because I couldn’t find any evidence that the phase 2 trial (for SPMS) with interferon is actually happening. The phase 1 trial should be over or ending soon and is for RRMS.

I removed “Interferon-tau (aka tauferon) (Pepgen)” from the phase 2 list because I can find no evidence that a trial is ongoing or that the company Pepgen still exists.

I added Masitinib to phase 2 based on this abstract from the upcoming AAN meeting, and this document (page 47).